On January 20, Gelonghui reported that Zhejiang East-Asia Pharmaceutical (605177.SH) announced the receipt of the Active Pharmaceutical Ingredient registration certificate from the South Korea Ministry of Food and Drug Safety (South Korea MFDS) for Luliconazole, which is used to treat superficial fungal infections caused by sensitive fungi such as tinea pedis, tinea corporis, and tinea cruris. It can also be used for cutaneous candidiasis and tinea versicolor. The company's Luliconazole Active Pharmaceutical Ingredient has obtained the registration certificate in South Korea, marking the eligibility for entry into the South Korean market, which will positively impact the company's expansion into the South Korean pharmaceutical market and help promote the sales of Luliconazole Active Pharmaceutical Ingredient in other overseas markets.
Clear
All
Quotes
News
Learn
Help
All
HK
US
CN
SG
AU
JP
All
News
Announcements
Reports
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
-
Hong Kong media: CKH HOLDINGS' plan to sell the port is postponed, and no contract will be signed next week.
U.S. Stock Market Preview | Core PCE exceeded expectations, with three major futures indices declining in the short term; Tesla rose nearly 1% in pre-market trading, while Musk stated that Trump would hold those who attacked Tesla accountable; AppLovin re
The State Administration for Market Regulation: Conducting an examination of CKH HOLDINGS port Trade in accordance with the law.
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
东亚药业(605177.SH):卢立康唑原料药获得韩国原料药品注册证书
Zhejiang East-Asia Pharmaceutical (605177.SH): Luliconazole Active Pharmaceutical Ingredient has obtained the Active Pharmaceutical Ingredient registration certificate from South Korea.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Like
Views 322
Write a comment
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report